相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension
Jasper Dingemanse et al.
EXPERT OPINION ON DRUG SAFETY (2014)
Pharmacokinetics of the Novel Dual Endothelin Receptor Antagonist Macitentan in Subjects With Hepatic or Renal Impairment
Patricia N. Sidharta et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Evaluation of the Endothelin Receptor Antagonists Ambrisentan, Bosentan, Macitentan, and Sitaxsentan as Hepatobiliary Transporter Inhibitors and Substrates in Sandwich-Cultured Human Hepatocytes
Eve-Irene Lepist et al.
PLOS ONE (2014)
Macitentan (Opsumit) for the treatment of pulmonary arterial hypertension
Megan Clarke et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2014)
Effect of Macitentan on Long-term Outcomes in Patients With Pulmonary Arterial Hypertension (PAH): Subanalysis of SERAPHIN Comparing Incident and Prevalent Patient Populations Not Treated With Background PAH-Specific Therapy
Gerald Simonneau et al.
CHEST (2013)
Investigation of the Effects of Ketoconazole on the Pharmacokinetics of Macitentan, a Novel Dual Endothelin Receptor Antagonist, in Healthy Subjects
Jacob Atsmon et al.
CLINICAL PHARMACOKINETICS (2013)
Interaction profile of macitentan, a new non-selective endothelin-1 receptor antagonist, in vitro
Johanna Weiss et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2013)
Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial
Ganesh Raghu et al.
EUROPEAN RESPIRATORY JOURNAL (2013)
Updated Treatment Algorithm of Pulmonary Arterial Hypertension
Nazzareno Galie et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Updated Clinical Classification of Pulmonary Hypertension
Gerald Simonneau et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension
Tomas Pulido et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Pharmacokinetics of Macitentan in Caucasian and Japanese Subjects: The Influence of Ethnicity and Sex
Shirin Bruderer et al.
PHARMACOLOGY (2013)
REDUCTION OF PULMONARY ARTERIAL HYPERTENSION (PAH)-RELATED HOSPITALIZATIONS WITH MACITENTAN IN THE RANDOMIZED CONTROLLED TRIAL SERAPHIN
R. N. Channick et al.
VALUE IN HEALTH (2013)
Therapies for pulmonary arterial hypertension: where are we today, where do we go tomorrow?
Andrei Seferian et al.
EUROPEAN RESPIRATORY REVIEW (2013)
Effect of Cyclosporine and Rifampin on the Pharmacokinetics of Macitentan, a Tissue-Targeting Dual Endothelin Receptor Antagonist
Shirin Bruderer et al.
AAPS JOURNAL (2012)
Nitrate-Nitrite-Nitric Oxide Pathway in Pulmonary Arterial Hypertension Therapeutics
Courtney E. Sparacino-Watkins et al.
CIRCULATION (2012)
The Discovery of N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N′-propylsulfamide (Macitentan), an Orally Active, Potent Dual Endothelin Receptor Antagonist
Martin H. Bolli et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Endothelin receptor antagonists for the treatment of pulmonary artery hypertension
Lewis J. Rubin
LIFE SCIENCES (2012)
Slow Receptor Dissociation Kinetics Differentiate Macitentan from Other Endothelin Receptor Antagonists in Pulmonary Arterial Smooth Muscle Cells
John Gatfield et al.
PLOS ONE (2012)
Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humans
Shirin Bruderer et al.
XENOBIOTICA (2012)
Pathways in pulmonary arterial hypertension: the future is here
Olivier Sitbon et al.
EUROPEAN RESPIRATORY REVIEW (2012)
Macitentan: entry-into-humans study with a new endothelin receptor antagonist
Patricia N. Sidharta et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2011)
ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association
Vallerie V. McLaughlin et al.
CIRCULATION (2009)
Guidelines for the diagnosis and treatment of pulmonary hypertension
Nazzareno Galie et al.
EUROPEAN HEART JOURNAL (2009)
End Points and Clinical Trial Design in Pulmonary Arterial Hypertension
Vallerie V. McLaughlin et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Cellular and Molecular Basis of Pulmonary Arterial Hypertension
Nicholas W. Morrell et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Diagnosis and Assessment of Pulmonary Arterial Hypertension
David B. Badesch et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Pulmonary hypertension
Gorev Grubu Uyeleri et al.
TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY (2009)
Endothelin receptor antagonists for pulmonary arterial hypertension - Rationale and place in therapy
Laura C. Price et al.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2008)
Pharmacology of Macitentan, an Orally Active Tissue-Targeting Dual Endothelin Receptor Antagonist
Marc Iglarz et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
An epidemiological study of pulmonary arterial hypertension
A. J. Peacock et al.
EUROPEAN RESPIRATORY JOURNAL (2007)
Pulmonary arterial hypertension in France - Results from a national registry
M Humbert et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2006)
The endothelin system in pulmonary arterial hypertension
N Galié et al.
CARDIOVASCULAR RESEARCH (2004)
Cellular and molecular pathobiology of pulmonary arterial hypertension
M Humbert et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2004)
分享论文
